相关实验视频

Updated: Jun 9, 2025

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

BIMZELX® (Bimekizumab-bkzx) 注射,用于皮下使用

Aditya K Gupta^1,2, Avantika Mann³, Kimberly Vincent⁴

¹Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.

|October 21, 2024

概括

在第三阶段试验中,比梅奇祖马布显著改善了斑块性牛皮的症状,实现了高皮肤清除率. 这种新的治疗方案在中度至重度牛皮患者中显示出强烈的疗效和良好的安全性.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
临床药理学临床药理学

背景情况:

牛皮是一种慢性炎症性皮肤疾病,影响全球数百万人.
目前对中度至重度斑块性牛皮的治疗包括针对特定炎症途径的生物药物.
对斑块性牛皮有必要制定有效且耐受良好的治疗方案.

研究的目的:

评估比梅奇祖马布在中度至重度斑块性牛皮的疗效和安全性.
为了在随机对照试验中将比梅奇祖马布与安慰剂,乌斯特基努马布和阿达利努马布进行比较.

主要方法:

进行了三项3期,随机,双盲,车辆和对比器控制的研究 (Be Vivid,Be Ready,Be Sure).
患有中度至重度斑块性牛皮的患者接受皮下用比梅奇祖马布,安慰剂,乌斯特基努马布或阿达利穆马布.
主要终点包括在牛皮区域和严重性指数 (PASI 90) 中实现90%的改善,并在第16周的调查员全球评估 (IGA) 评分为0或1.

主要成果:

毕梅奇祖马布在各项研究中,在85-91%的患者中实现了PASI 90,而在比较者中达到5-50%.
84-93%的患者获得了IGA 0/1分数,而对比剂患者则为5-57%.
比梅基祖马布表现出耐受性良好的安全性,没有意外发现.

结论:

比梅基祖马布是适度至重症斑块性牛皮的高效治疗方法.
与安慰剂和现有的生物药物相比,毕梅奇祖马布在皮肤清除方面提供了显著的改善.
比梅基祖马布的安全性支持其在临床实践中用于斑块性牛皮的治疗.

更多相关视频

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

相关概念视频

Drug Delivery: Parenteral Route

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...